Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Doxil for Metastatic Renal Cell Carcinoma
NCT00630409Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Sep 2004
- Primary completion
- Sep 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, pegylated liposomal doxorubicin in metastatic renal cell carcinoma (mRCC), sponsored by University of Pittsburgh. Started Sep 2004; status: completed.
02
Drugs
gemcitabinepegylated liposomal doxorubicin
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00630409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630409.